The effect of strontium incorporation into sol-gel biomaterials on their protein adsorption and cell interactions

[EN] It is known strontium can both inhibit the osteoclast formation and stimulate the osteoblast maturation, so biomaterials containing this element can favour bone structure stabilisation. The addition of Sr to biomaterials could affect their interactions with proteins and cells. Here, a silica-hybrid sol-gel network doped with different amounts of SrCl2 and applied as coatings on titanium discs was examined. in vitro analysis was performed to determine the potential effect of Sr in the coatings, showing enhanced gene expression of osteogenic markers (alkaline phosphatase and transforming growth factor-beta) in MC3T3-E1 incubated with Sr-doped biomaterials. The examination of inflammatory markers (tumour necrosis factor-alpha and interleukin 10) in RAW 264.7 macrophages revealed an anti-inflammatory potential of these materials. Proteins adsorbed onto the coatings incubated with human serum (3 h at 37 degrees C) were also analysed; mass spectrometry was used to characterise the proteins adhering to materials with different Sr content. Adding Sr to the coatings increased their affinity to APOE and VTNC proteins (associated with anti-inflammatory and osteogenic functions). Moreover, the proteins involved in coagulation processes, such as prothrombin, were more abundant on the coatings containing Sr than on the base sol-gel surfaces. Correlations between gene expression and proteomic results were also examined.This work was supported by MINECO (MAT2017-86043-R); Universitat Jaume I (grant numbers Predoc/2014/25, UJI-B2017-37); Basque Government (grant numbers IT611-13, Predoc/2016/1/0141), and University of the Basque Country (UFI11/56). Authors would like to thank Antonio Coso and Jaime Franco (GMI-Ilerimplant) for their inestimable contribution to this study, and Raquel Oliver, Jose Ortega (UJI), and Iraide Escobes (CIC bioGUNE) for their valuable technical assistance.Romero-Gavilán, F.; Araújo-Gomes, N.; García-Arnáez, I.; Martínez-Ramos, C.; Elortza, F.; Azkargorta, M.; Iloro, I.... (2019). The effect of strontium incorporation into sol-gel biomaterials on their protein adsorption and cell interactions. Colloids and Surfaces B Biointerfaces. 174:9-16. https://doi.org/10.1016/j.colsurfb.2018.10.075S91617

Proteomic analysis of calcium-enriched sol-gel biomaterials

[EN] Calcium is an element widely used in the development of biomaterials for bone tissue engineering as it plays important roles in bone metabolism and blood coagulation. The Ca ions can condition the microenvironment at the tissue-material interface, affecting the protein deposition process and cell responses. The aim of this study was to analyze the changes in the patterns of protein adsorption on the silica hybrid biomaterials supplemented with different amounts of CaCl2, which can function as release vehicles. This characterization was carried out by incubating the Ca-biomaterials with human serum. LC-MS/MS analysis was used to characterize the adsorbed protein layers and compile a list of proteins whose affinity for the surfaces might depend on the CaCl2 content. The attachment of pro- and anti-clotting proteins, such as THRB, ANT3, and PROC, increased significantly on the Ca-materials. Similarly, VTNC and APOE, proteins directly involved on osteogenic processes, attached preferentially to these surfaces. To assess correlations with the proteomic data, these formulations were tested in vitro regarding their osteogenic and inflammatory potential, employing MC3T3-E1 and RAW 264.7 cell lines, respectively. The results confirmed a Ca dose-dependent osteogenic and inflammatory behavior of the materials employed, in accordance with the protein attachment patterns.This work was supported by MINECO [MAT2017-86043-R]; Universitat Jaume I [Grant numbers Predoc/2014/25, UJI-B2017-37]; Basque Government [Grant numbers IT611-13, Predoc/2016/1/0141]; University of the Basque Country [Grant number UFI11/56]. CIC bioGUNE is supported by Basque Department of Industry, Tourism and Trade (Etortek and Elkartek programs), the Innovation Technology Department of the Bizkaia County; The ProteoRed-ISCIII (Grant PRB3 IPT17/0019); CIBERehd Network, and Severo Ochoa Grant (SEV-2016-0644). Authors would like to thank Antonio Coso and Jaime Franco (GMI-Ilerimplant) for their inestimable contribution to this study, and Raquel Oliver, Jose Ortega (UJI) and Iraide Escobes (CIC bioGUNE) for their valuable technical assistance.Romero-Gavilán, F.; Araújo-Gomes, N.; Cerqueira, A.; García-Arnáez, I.; Martínez-Ramos, C.; Azkargorta, M.; Iloro, I.... (2019). Proteomic analysis of calcium-enriched sol-gel biomaterials. JBIC Journal of Biological Inorganic Chemistry. 24(4):563-574. https://doi.org/10.1007/s00775-019-01662-5S563574244Berridge MJ, Bootman MD, Lipp P (1998) Calcium—a life and death signal. Nature 395:645–648. https://doi.org/10.1038/27094Hoppe A, Güldal NS, Boccaccini AR (2011) A review of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics. Biomaterials 32:2757–2774. https://doi.org/10.1016/j.biomaterials.2011.01.004Flynn A (2003) The role of dietary calcium in bone health. Proc Nutr Soc 62:851–858. https://doi.org/10.1079/PNS2003301Marie PJ (2010) The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46:571–576. https://doi.org/10.1016/j.bone.2009.07.082Honda Y, Fitzsimmons RJ, Baylink DJ, Mohan S (1995) Effects of extracellular calcium on insulin-like growth factor II in human bone cells. J Bone Miner Res 10:1660–1665. https://doi.org/10.1002/jbmr.5650101108Koori K, Maeda H, Fujii S et al (2014) The roles of calcium-sensing receptor and calcium channel in osteogenic differentiation of undifferentiated periodontal ligament cells. Cell Tissue Res 357:707–718. https://doi.org/10.1007/s00441-014-1918-5Habibovic P, Barralet JE (2011) Bioinorganics and biomaterials: bone repair. Acta Biomater 32:3013–3026. https://doi.org/10.1016/j.actbio.2011.03.027Oshiro Junior J, Paiva Abuçafy M, Berbel Manaia E et al (2016) Drug delivery systems obtained from silica based organic-inorganic hybrids. Polymers (Basel) 8:91. https://doi.org/10.3390/polym8040091Jones JR (2015) Reprint of: review of bioactive glass: from hench to hybrids. Acta Biomater 23:S53–S82. https://doi.org/10.1016/j.actbio.2015.07.019Romero-Gavilán F, Barros-Silva S, García-Cañadas J et al (2016) Control of the degradation of silica sol-gel hybrid coatings for metal implants prepared by the triple combination of alkoxysilanes. J Non Cryst Solids 453:66–73. https://doi.org/10.1016/j.jnoncrysol.2016.09.026Martínez-Ibáñez M, Juan-Díaz MJ, Lara-Saez I et al (2016) Biological characterization of a new silicon based coating developed for dental implants. J Mater Sci Mater Med 27:80. https://doi.org/10.1007/s10856-016-5690-9Martínez-Ibáñez M, Murthy NS, Mao Y et al (2018) Enhancement of plasma protein adsorption and osteogenesis of hMSCs by functionalized siloxane coatings for titanium implants. J Biomed Mater Res Part B Appl Biomater 106:1138–1147. https://doi.org/10.1002/jbm.b.33889Salinas AJ, Merino JM, Babonneau F et al (2007) Microstructure and Macroscopic Properties of Bioactive CaO–SiO2–PDMS Hybrids. J Biomed Mater Res B Appl Biomater 81B:274–282. https://doi.org/10.1002/jbm.b.30663Almeida JC, Wacha A, Gomes PS et al (2016) A biocompatible hybrid material with simultaneous calcium and strontium release capability for bone tissue repair. Mater Sci Eng, C 62:429–438. https://doi.org/10.1016/j.msec.2016.01.083Valliant EM, Romer F, Wang D et al (2013) Bioactivity in silica/poly(c-glutamic acid) sol-gel hybrids through calcium chelation. Acta Biomater 9:7662–7671. https://doi.org/10.1016/j.actbio.2013.04.037Shirosaki Y, Tsuru K, Hayakawa S et al (2005) In vitro cytocompatibility of MG63 cells on chitosan-organosiloxane hybrid membranes. Biomaterials 26:485–493. https://doi.org/10.1016/j.biomaterials.2004.02.056Romero-Gavilán F, Gomes NC, Ródenas J et al (2017) Proteome analysis of human serum proteins adsorbed onto different titanium surfaces used in dental implants. Biofouling 33:98–111. https://doi.org/10.1080/08927014.2016.1259414Hirsh SL, McKenzie DR, Nosworthy NJ et al (2013) The Vroman effect: competitive protein exchange with dynamic multilayer protein aggregates. Colloids Surfaces B Biointerfaces 103:395–404. https://doi.org/10.1016/j.colsurfb.2012.10.039Chen Z, Klein T, Murray RZ et al (2015) Osteoimmunomodulation for the development of advanced bone biomaterials. Mater Today 19:304–321. https://doi.org/10.1016/j.mattod.2015.11.004Araújo-Gomes N, Romero-Gavilán F, García-Arnáez I et al (2018) Osseointegration mechanisms: a proteomic approach. J Biol Inorg Chem 23:459–470. https://doi.org/10.1007/s00775-018-1553-9Romero-Gavilán F, Sanchez-Pérez AM, Araújo-Gomes N et al (2017) Proteomic analysis of silica hybrid sol-gel coatings: a potential tool for predicting the biocompatibility of implants in vivo. Biofouling 33:676–689. https://doi.org/10.1080/08927014.2017.1356289Araújo-Gomes N, Romero-Gavilán F, Sanchez-Pérez AM et al (2018) Characterization of serum proteins attached to distinct sol-gel hybrid surfaces. J Biomed Mater Res Part B Appl Biomater 106:1477–1485. https://doi.org/10.1002/jbm.b.33954Romero-Gavilan F, Araújo-Gomes N, Sánchez-Pérez AM et al (2017) Bioactive potential of silica coatings and its effect on the adhesion of proteins to titanium implants. Colloids Surfaces B Biointerfaces 162:316–325. https://doi.org/10.1016/j.colsurfb.2017.11.072Shiu HT, Goss B, Lutton C et al (2014) Formation of blood clot on biomaterial implants influences bone healing. Tissue Eng Part B Rev 20:697–712. https://doi.org/10.1089/ten.teb.2013.0709Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6:3–8. https://doi.org/10.1038/NMETH.1322Dvorak MM, Riccardi D (2004) Ca2 + as an extracellular signal in bone. Cell Calcium 35:249–255. https://doi.org/10.1016/j.ceca.2003.10.014Cho NH, Seong SY (2009) Apolipoproteins inhibit the innate immunity activated by necrotic cells or bacterial endotoxin. Immunology 128:479–486. https://doi.org/10.1111/j.1365-2567.2008.03002.xMeerasa A, Huang JG, Gu FX (2013) Human serum lipoproteins influence protein deposition patterns on nanoparticle surfaces. ACS Appl Mater Interfaces 5:489–493. https://doi.org/10.1021/am302554qBaitsch D, Bock HH, Engel T et al (2011) Apolipoprotein e induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol 31:1160–1168. https://doi.org/10.1161/ATVBAHA.111.222745Niemeier A, Schinke T, Heeren J, Amling M (2012) The role of Apolipoprotein E in bone metabolism. Bone 50:518–524. https://doi.org/10.1016/j.bone.2011.07.015Kim WS, Kim HJ, Lee ZH et al (2013) Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB. Exp Cell Res 319:436–446. https://doi.org/10.1016/j.yexcr.2012.12.004Emsley J, White HE, O’Hara BP et al (1994) Structure of pentameric human serum amyloid P component. Nature 367:338–345Poulsen ET, Pedersen KW, Marzeda AM, Enghild JJ (2017) Serum amyloid P component (SAP) interactome in human plasma containing physiological calcium levels. Biochemistry 56:896–902. https://doi.org/10.1021/acs.biochem.6b01027Bottazzi B, Inforzato A, Messa M et al (2016) The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol 64:1416–1427. https://doi.org/10.1016/j.jhep.2016.02.029Mollnes TE, Kirschfink M (2006) Strategies of therapeutic complement inhibition. Mol Immunol 43:107–121. https://doi.org/10.1016/j.molimm.2005.06.014Gessmann J, Seybold D, Peter E et al (2013) Plasma clots gelled by different amounts of calcium for stem cell delivery. Langenbeck’s Arch Surg 398:161–167. https://doi.org/10.1007/s00423-012-1015-8Scheraga HA (2004) The thrombin-fibrinogen interaction. Biophys Chem 112:117–130. https://doi.org/10.1016/j.bpc.2004.07.011Chu AJ (2010) Blood coagulation as an intrinsic pathway for proinflammation: a mini review. Inflamm Allergy Drug Targets 9:32–44. https://doi.org/10.2174/187152810791292890Suleiman L, Négrier C, Boukerche H (2013) Protein S: a multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit Rev Oncol Hematol 88:637–654. https://doi.org/10.1016/j.critrevonc.2013.07.004Furie B, Furie BC (2008) Mechanisms of thrombus formation. N Engl J Med 359:938–949. https://doi.org/10.1056/NEJMra0801082Biltoft D, Gram JB, Larsen A et al (2017) Fast form alpha-2-macroglobulin—a marker for protease activation in plasma exposed to artificial surfaces. Clin Biochem 50:1203–1208. https://doi.org/10.1016/j.clinbiochem.2017.09.002Cvirn G, Gallistl S, Koestenberger M et al (2002) Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res 105:433–439. https://doi.org/10.1016/S0049-3848(02)00042-7Vogler EA, Siedlecki CA (2009) Contact activation of blood-plasma coagulation. Biomaterials 30:1857–1869. https://doi.org/10.1016/j.biomaterials.2008.12.041Leavesley DI, Kashyap AS, Croll T et al (2013) Vitronectin—master controller or micromanager? IUBMB Life 65:807–818. https://doi.org/10.1002/iub.1203Kundu AK, Putnam AJ (2006) Vitronectin and collagen I differentially regulate osteogenesis in mesenchymal stem cells. Biochem Biophys Res Commun 347:347–357. https://doi.org/10.1016/j.bbrc.2006.06.110Cacchioli A, Ravanetti F, Bagno A et al (2009) Human vitronectin-derived peptide covalently grafted onto titanium surface improves osteogenic activity: a pilot in vivo study on rabbits. Tissue Eng Part A 15:2017–2026. https://doi.org/10.1089/ten.tea.2008.054

Complement proteins regulating macrophage polarisation on biomaterials

[EN] One of the events occurring when a biomaterial is implanted in an host is the protein deposition onto its surface, which might regulate cell responses. When a biomaterial displays a compromised biocompatibility, distinct complement pathways can be activated to produce a foreign body reaction. In this article, we have designed different types of biomaterial surfaces to study the inflammation process. Here, we used different concentrations of (3-glycidoxypropyl)-trimethoxysilane (GPTMS), an organically-modified alkoxysilane as a precursor for the synthesis of various types of sol-gel materials functionalizing coatings for titanium implants to regulate biological responses. Our results showed that greater GPTMS surface concentrations induced greater secretion of TNF-alpha and IL-10 on RAW 264.7 macrophages. When implanted into rabbit tibia, osseointegration decreased with higher GPTMS concentrations. Interestingly, higher deposition of complement-related proteins C-reactive protein (CRP) and ficolin-2 (FCN2), two main activators of distinct complement pathways, was observed. Taking all together, inflammatory potential increase seems to be GPTMS concentration-dependent. Our results show that a greater adsorption of complement proteins can condition macrophage polarization.This work was supported by MINECO [MAT2017-86043-R]; Universitat Jaume I [Predoc/2014/25, UJI-B2017-37]; Basque Government [IT611-13, Predoc/2016/1/0141]; University of the Basque Country [UFI11/56]; CIC bioGUNE is supported by Basque Department of Industry, Tourism and Trade (Etortek and Elkartek programs), ProteoRed-ISCIII [PRB3 IPT17/0019]; CIBERehd Network and Severo Ochoa Grant [SEV-2016-0644]. Authors would like to thank Antonio Coso and Jaime Franco (GMI-Ilerimplant) for their inestimable contribution to this study, and Raquel Oliver, Jose Ortega (UJI), René van Rheden, Vicent Cuijpers (Radboudumc) and Iraide Escobes (CIC bioGUNE) for their valuable technical assistance.Araújo-Gomes, N.; Romero-Gavilán, F.; Zhang, Y.; Martínez-Ramos, C.; Elortza, F.; Azkargorta, M.; Martín De Llano, JJ.... (2019). Complement proteins regulating macrophage polarisation on biomaterials. Colloids and Surfaces B Biointerfaces. 181:125-133. https://doi.org/10.1016/j.colsurfb.2019.05.039S12513318

2 deoxy-D-glucose augments the mitochondrial respiratory chain in heart

2-Deoxy-D-glucose (2DG) has recently received emergency approval for the treatment of COVID-19 in India, after a successful clinical trial. SARS-CoV-2 infection of cultured cells is accompanied by elevated glycolysis and decreased mitochondrial function, whereas 2DG represses glycolysis and stimulates respiration, and restricts viral replication. While 2DG has pleiotropic effects on cell metabolism in cultured cells it is not known which of these manifests in vivo. On the other hand, it is known that 2DG given continuously can have severe detrimental effects on the rodent heart. Here, we show that the principal effect of an extended, intermittent 2DG treatment on mice is to augment the mitochondrial respiratory chain proteome in the heart; importantly, this occurs without vacuolization, hypertrophy or fibrosis. The increase in the heart respiratory chain proteome suggests an increase in mitochondrial oxidative capacity, which could compensate for the energy deficit caused by the inhibition of glycolysis. Thus, 2DG in the murine heart appears to induce a metabolic configuration that is the opposite of SARS-CoV-2 infected cells, which could explain the compound's ability to restrict the propagation of the virus to the benefit of patients with COVID-19 disease

Smelling the dark proteome: Functional characterization of PITH domain-containing protein 1 (C1orf128) in olfactory metabolism

The Human Proteome Project (HPP) consortium aims to functionally characterize the dark proteome. On the basis of the relevance of olfaction in early neurodegeneration, we have analyzed the dark proteome using data mining in public resources and omics data sets derived from the human olfactory system. Multiple dark proteins localize at synaptic terminals and may be involved in amyloidopathies such as Alzheimer’s disease (AD). We have characterized the dark PITH domain-containing protein 1 (PITHD1) in olfactory metabolism using bioinformatics, proteomics, in vitro and in vivo studies, and neuropathology. PITHD1–/– mice exhibit olfactory bulb (OB) proteome changes related to synaptic transmission, cognition, and memory. OB PITHD1 expression increases with age in wild-type (WT) mice and decreases in Tg2576 AD mice at late stages. The analysis across 6 neurological disorders reveals that olfactory tract (OT) PITHD1 is specifically upregulated in human AD. Stimulation of olfactory neuroepithelial (ON) cells with PITHD1 alters the ON phosphoproteome, modifies the proliferation rate, and induces a pro-inflammatory phenotype. This workflow applied by the Spanish C-HPP and Human Brain Proteome Project (HBPP) teams across the ON-OB-OT axis can be adapted as a guidance to decipher functional features of dark proteins. Data are available via ProteomeXchange with identifiers PXD018784 and PXD021634

Targeting UBC9-Mediated Protein Hyper-SUMOylation in Cystic Cholangiocytes Halts Polycystic Liver Disease in Experimental Models

BACKGROUND & AIMS: Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of multiple fluid-filled biliary cysts. Most PLD-causative genes participate in protein biogenesis and/or transport. Post-translational modifications (PTMs) are implicated in protein stability, localization and activity, contributing to human pathobiology; however, their role in PLD is unknown. Herein, we aimed to unveil the role of protein SUMOylation in PLD and its potential therapeutic targeting. METHODS: Levels and functional effects of SUMOylation, along with response to S-adenosylmethionine (SAMe, inhibitor of the SUMOylation enzyme UBC9) and/or short-hairpin RNAs (shRNAs) against UBE2I (UBC9), were evaluated invitro, invivo and/or in patients with PLD. SUMOylated proteins were determined by immunoprecipitation and proteomic analyses by mass spectrometry. RESULTS: Most SUMOylation-related genes were found overexpressed (mRNA) in polycystic human and rat liver tissue, as well as in cystic cholangiocytes in culture compared to controls. Increased SUMOylated protein levels were also observed in cystic human cholangiocytes in culture, which decreased after SAMe administration. Chronic treatment of polycystic (PCK: Pkdh1-mut) rats with SAMe halted hepatic cystogenesis and fibrosis, and reduced liver/body weight ratio and liver volume. Invitro, both SAMe and shRNA-mediated UBE2I knockdown increased apoptosis and reduced cell proliferation of cystic cholangiocytes. High-throughput proteomic analysis of SUMO1-immunoprecipitated proteins in cystic cholangiocytes identified candidates involved in protein biogenesis, ciliogenesis and proteasome degradation. Accordingly, SAMe hampered proteasome hyperactivity in cystic cholangiocytes, leading to activation of the unfolded protein response and stress-related apoptosis. CONCLUSIONS: Cystic cholangiocytes exhibit increased SUMOylation of proteins involved in cell survival and proliferation, thus promoting hepatic cystogenesis. Inhibition of protein SUMOylation with SAMe halts PLD, representing a novel therapeutic strategy. LAY SUMMARY: Protein SUMOylation is a dynamic post-translational event implicated in numerous cellular processes. This study revealed dysregulated protein SUMOylation in polycystic liver disease, which promotes hepatic cystogenesis. Administration of S-adenosylmethionine (SAMe), a natural UBC9-dependent SUMOylation inhibitor, halted polycystic liver disease in experimental models, thus representing a potential therapeutic agent for patients.Spanish Carlos III Health Institute (ISCIII) [J.M. Banales (FIS PI12/00380, PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129 and CPII19/00008); M.J. Perugorria (FIS PI14/00399, PI17/00022 and PI20/00186); P.M. Rodrigues (Sara Borrell CD19/00254)] cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER); Ministerio de Ciencia, Innovación y Universidades (MICINN; M.L. Martinez-Chantar: SAF2017-87301-R); “Instituto de Salud Carlos III” [CIBERehd: J.M. Banales, M.J. Perugorria, M.L. Martinez-Chantar and L. Bujanda], Spain; “Diputación Foral Gipuzkoa” (J.M. Banales: DFG15/010, DFG16/004), Department of Health of the Basque Country (M.J. Perugorria: 2019111024, 2015111100 and J.M. Banales: 2017111010), “Euskadi RIS3” (J.M. Banales: 2016222001, 2017222014, 2018222029, 2019222054, 2020333010), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M. Banales and M.L. Martinez-Chantar) and Department of Industry of the Basque Country (J.M. Banales: Elkartek: KK-2020/00008). La Caixa Scientific Foundation (J.M. Banales and M.L. Martinez-Chantar: HR17-00601). “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation, to J.M. Banales and M.L. Martinez-Chantar). “Ayudas para apoyar grupos de investigación del Sistema Universitario Vasco” (IT971-16 to P.A.). Università Politecnica delle Marche PSA2017_UNIVPM grant (to M. Marzioni). National Institutes of Health (NIH) of United States of America (DK24031 to N.F. LaRusso). MJ Perugorria was funded by the Spanish Ministry of Economy and Competitiveness (MINECO: “Ramón y Cajal” Program RYC-2015-17755), P.Y. Lee-Law by the European Association for the Study of the Liver (EASL; Sheila Sherlock Award 2017), F.J. Caballero-Camino by the Spanish Ministry of Science and Innovation (BES-2014-069148), and P. Olaizola and A. Santos-Laso by the Basque Government (PRE_2016_1_0269, PRE_2015_1_0126). We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644). The funding sources had no involvement in study design, data collection and analysis, decision to publish, or preparation of the article

Identification of proximal SUMO-dependent interactors using SUMO-ID

The fast dynamics and reversibility of posttranslational modifications by the ubiquitin family pose significant challenges for research. Here we present SUMO-ID, a technology that merges proximity biotinylation by TurboID and protein-fragment complementation to find SUMO-dependent interactors of proteins of interest. We develop an optimized split-TurboID version and show SUMO interaction-dependent labelling of proteins proximal to PML and RANGAP1. SUMO-dependent interactors of PML are involved in transcription, DNA damage, stress response and SUMO modification and are highly enriched in SUMO Interacting Motifs, but may only represent a subset of the total PML proximal proteome. Likewise, SUMO-ID also allow us to identify interactors of SUMOylated SALL1, a less characterized SUMO substrate. Furthermore, using TP53 as a substrate, we identify SUMO1, SUMO2 and Ubiquitin preferential interactors. Thus, SUMO-ID is a powerful tool that allows to study the consequences of SUMO-dependent interactions, and may further unravel the complexity of the ubiquitin code.Cancer Signaling networks and Molecular Therapeutic

Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

[Background and Aims] Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with a dismal prognosis. We investigated if lipid metabolism is disrupted in CCA and its role in tumor proliferation.[Approach and Results] The in vitro and in vivo tumorigenic capacity of five human CCA cell lines was analyzed. Proteome, lipid content, and metabolic fluxes were evaluated in CCA cells and compared with normal human cholangiocytes (NHC). The Akt1/NOTCH1 intracellular cytoplasmic domain (Nicd1)-driven CCA mouse model was also evaluated. The proteome of CCA cells was enriched in pathways involved in lipid and lipoprotein metabolism. The EGI1 CCA cell line presented the highest tumorigenic capacity. Metabolic studies in high (EGI1) versus low (HUCCT1) proliferative CCA cells in vitro showed that both EGI1 and HUCCT1 incorporated more fatty acids (FA) than NHC, leading to increased triglyceride storage, also observed in Akt1/Nicd1-driven CCA mouse model. The highly proliferative EGI1 CCA cells showed greater uptake of very-low-density and HDLs than NHC and HUCCT1 CCA cells and increased cholesteryl ester content. The FA oxidation (FAO) and related proteome enrichment were specifically up-regulated in EGI1, and consequently, pharmacological blockade of FAO induced more pronounced inhibition of their tumorigenic capacity compared with HUCCT1. The expression of acyl-CoA dehydrogenase ACADM, the first enzyme involved in FAO, was increased in human CCA tissues and correlated with the proliferation marker PCNA.[Conclusions] Highly proliferative human CCA cells rely on lipid and lipoprotein uptake to fuel FA catabolism, suggesting that inhibition of FAO and/or lipid uptake could represent a therapeutic strategy for this CCA subclass.This work was supported by “Ayudas para apoyar grupos de investigación del sistema Universitario Vasco” (IT971‐16 to PA), MCIU/AEI/FEDER, UE (2018‐095134‐B‐100 to PA and by the University of Basque Country COLAB20/01 to PA; Spanish Carlos III Health Institute (ISCIII) (FIS PI15/01132, PI18/01075, PI21/00922, and Miguel Servet Program CON14/00129 and CPII19/00008 to JMB; FIS PI14/00399, PI17/00022 and PI20/00186 to MJP; Sara Borrell [CD19/00254 to PMR]) cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER); CIBERehd (ISCIII) to JMB, MJP, PMR, PA and LB); “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to JMB and 2020‐CIEN‐000067‐01 to PMR), Department of Health of the Basque Country (2019111024 to MJP, 2017111010 to JMB, and 2020111077 to JMB and PA), “Euskadi RIS3” (2016222001, 2017222014, 2018222029, 2019222054, 2020333010 to JMB), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to JMB) and Department of Industry of the Basque Country (Elkartek: KK‐2020/00008 to JMB); La Caixa Scientific Foundation (HR17‐00601 to JMB). “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation, to JMB). AMMF‐The Cholangiocarcinoma Charity (EU/2019/AMMFt/001, to JMB and PMR). MRDG was funded by “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC de Bizkaia), MJP was funded by the Spanish Ministry of Economy and Competitiveness (MINECO: “Ramón y Cajal” Program RYC‐2015‐17755), IL, AL and FG‐R by the Basque Government (PRE_2016_1_0152, PRE_2018_2_0195 and PRE 2020 2 02500, respectively), AN‐Z and BG‐S by the UPV/EHU, AB‐V by “Programa de especialización de Personal Investigador Doctor” at the UPV/EHU (2019‐2020) and MA by the MCIU/AEI/FEDER

Characterization of preovulatory follicular fluid secretome and its effects on equine oocytes during in vitro maturation

12 Pág.In vitro maturation (IVM) of oocytes is clinically used in horses to produce blastocysts but current conditions used for horses are suboptimal. We analyzed the composition of equine preovulatory follicular fluid (FF) secretome and tested its effects on meiotic competence and gene expression in oocytes subjected to IVM. Preovulatory FF was obtained, concentrated using ultrafiltration with cut-off of 10 kDa, and stored at -80 °C. The metabolic and proteomic composition was analyzed, and its ultrastructural composition was assessed by cryo-transmission microscopy. Oocytes obtained post-mortem or by ovum pick up (OPU) were subjected to IVM in the absence (control) or presence of 20 or 40 μg/ml (S20 or S40) of secretome. Oocytes were then analyzed for chromatin configuration or snap frozen for gene expression analysis. Proteomic analysis detected 255 proteins in the Equus caballus database, mostly related to the complement cascade and cholesterol metabolism. Metabolomic analysis yielded 14 metabolites and cryo-transmission electron microscopy analysis revealed the presence of extracellular vesicles (EVs). No significant differences were detected in maturation rates among treatments. However, the expression of GDF9 and BMP15 significantly increased in OPU-derived oocytes compared to post-mortem oocytes (fold increase ± SEM: 9.4 ± 0.1 vs. 1 ± 0.5 for BMP15 and 9.9 ± 0.3 vs. 1 ± 0.5 for GDF9, respectively; p < 0.05). Secretome addition increased the expression of TNFAIP6 in S40 regardless of the oocyte source. Further research is necessary to fully understand whether secretome addition influences the developmental competence of equine oocytes.Projects PID2020-112723RB-I00 and PID2021-122507OB-I00 funded by MCIN1/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. José Manuel Ortiz Rodríguez was funded by PNR - DIMIVET- University of Bologna - CUP J45F21002000001, Ministry of University and Research (D.M. 737/2021). This work was supported by ‘Junta de Extremadura’ (Spain) and ‘Fondo Europeo de Desarrollo Regional’; Reference: IB20005. Marcos Luis Calero was supported by a grant “Plan Propio de Iniciación a la Investigación, Desarrollo Tecnológico e Innovación. Acción II” from the University of Extremadura (Ref. Beca RC1). Grant FJC2021-047675-I funded by MCIN2/AEI /10.13039/501100011033 and European Union NextGenerationEU/PRTR to Federica Marinaro. We appreciate the kind help of Paula Navarrete López for proteomic figures handling. The help of the veterinary staff of the INCARSA abbatoir is greatly acknowledged. This paper is dedicated to de memory of Dr. Juan Florencio Macías Núñez who seeded the curiosity and love for research in B. M-G.Peer reviewe

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent.

BACKGROUND AND AIMS Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. APPROACH AND RESULTS C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD + /NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. CONCLUSIONS Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD.This work was supported by grants from Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for Jorge Simon and Maria Luz Martinez-Chantar); Ministerio de Economía, Industria y Competitividad, Retos a la Sociedad AGL2017- 86927R (for F.M.); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 and DTS21/00094 (for Jorge Simon and Maria Luz Martinez-Chantar, and Asis Palazon. respectively); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by European Regional Development Fund/European Social Fund, “Investing in your future” PI19/00819, “Una manera de hacer Europa” FIS PI20/00765, and PI21/01067 (for Jose J. G. Marin., Pau Sancho-Bru,. and Mario F. Fraga respectively); Departamento de Industria del Gobierno Vasco (for Maria Luz Martinez-Chantar); Asturias Government (PCTI) co-funding 2018-2023/ FEDER IDI/2021/000077 (for Mario F. Fraga.); Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00, CEX2021-001136-S PID2020-117941RB-I00, PID2020-11827RB-I00 and PID2019-107956RA-100 integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER (for Maria Luz Martinez-Chantar, Francisco J Cubero., Yulia A Nevzorova and Asis Palazon); Ayudas Ramón y Cajal de la Agencia Estatal de Investigación RY2013-13666 and RYC2018- 024183-I (for Leticia Abecia and Asis Palazon); European Research Council Starting Grant 804236 NEXTGEN-IO (for Asis Palazon); The German Research Foundation SFB/TRR57/P04, SFB1382-403224013/ A02 and DFG NE 2128/2-1 (for Francisco J Cubero and Yulia A Nevzorova); National Institute of Health (NIH)/National Institute of Alcohol Abuse and Alcoholism (NIAAA) 1U01AA026972-01 (For Pau Sancho-Bru); Junta de Castilla y León SA074P20 (for Jose J. G. Marin); Junta de Andalucía, Grupo PAIDI BIO311 (for Franz Martin); CIBERER Acciones Cooperativas y Complementarias Intramurales ACCI20-35 (for Mario F. Fraga); Ministerio de Educación, Cultura y Deporte FPU17/04992 (for Silvia Ariño); Fundació Marato TV3 201916-31 (for Jose J. G. Marin.); Ainize Pena-Cearra is a fellow of the University of the Basque Country (UPV/ EHU); BIOEF (Basque Foundation for Innovation and Health Research); Asociación Española contra el Cáncer (Maria Luz Martinez-Chantar and Teresa C. Delgado.); Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for Maria Luz Martinez-Chantar); La Caixa Foundation Program (for Maria Luz Martinez-Chantar); Proyecto Desarrollo Tecnologico CIBERehd (for Maria Luz Martinez-Chantar); Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III.S